title: Hallucinations treated with rivastigmine in Creutzfeldt-Jakob disease.
abstract: Clinical features at onset of Creutzfeldt-Jakob disease (CJD) may mimic symptoms of Lewy bodies dementia. Clinical evolution, neuroimaging, metabolism exploration, and cerebrospinal fluid investigations may help establishing the diagnosis. However, CJD definite diagnosis requires postmortem autopsy. This symptom overlap led us to successfully prescribe an anticholinesterasic treatment, rivastigmine, to a patient for whom a probable CJD disease was finally diagnosed.
authors.affiliation: CHU Grenoble - Pharmacy, BP217, 38043 Grenoble, France CHU Grenoble - Neurology, Grenoble, France. cchapuis1@chu-grenoble.fr
authors.forename: Claire
authors.initials: C
authors.lastname: Chapuis
authors.forename: Olivier
authors.initials: O
authors.lastname: Casez
authors.forename: Emmeline
authors.initials: E
authors.lastname: Lagrange
authors.forename: Pierrick
authors.initials: P
authors.lastname: Bedouch
authors.forename: Gérard
authors.initials: G
authors.lastname: Besson
mesh_terms: D000368:Aged; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D007562:Creutzfeldt-Jakob Syndrome / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006212:Hallucinations / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D020961:Lewy Body Disease / Q000175:diagnosis; D048448:Phenylcarbamates / Q000627:therapeutic use*; D000068836:Rivastigmine; D016896:Treatment Outcome
chemical_list: D002800:Cholinesterase Inhibitors; D048448:Phenylcarbamates; D000068836:Rivastigmine